{
  "ticker": "VOR",
  "company_name": "Vor Biopharma Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05306574",
      "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Systemic Lupus Erythematosus",
      "start_date": "2022-06-20",
      "completion_date": "2025-01-06",
      "enrollment": 0,
      "sponsor": "Vor Biopharma"
    },
    {
      "nct_id": "NCT05309733",
      "title": "A Long-term Follow-up Study of Patients Who Received VOR33",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Leukemia, Myeloid, Acute",
      "start_date": "2022-04-15",
      "completion_date": "2025-05-28",
      "enrollment": 0,
      "sponsor": "Vor Biopharma"
    },
    {
      "nct_id": "NCT05984199",
      "title": "Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Leukemia, Myeloid, Acute",
      "start_date": "2023-12-11",
      "completion_date": "2025-05-28",
      "enrollment": 0,
      "sponsor": "Vor Biopharma"
    },
    {
      "nct_id": "NCT06456567",
      "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)",
      "status": "WITHDRAWN",
      "phase": "PHASE3",
      "condition": "Systemic Lupus Erythematosus",
      "start_date": "2024-09",
      "completion_date": "2025-01-06",
      "enrollment": 0,
      "sponsor": "Vor Biopharma"
    },
    {
      "nct_id": "NCT06456580",
      "title": "A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Generalized Myasthenia Gravis",
      "start_date": "2024-07-17",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "Vor Biopharma"
    },
    {
      "nct_id": "NCT04849910",
      "title": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Leukemia, Myeloid, Acute, Myelodysplastic Syndromes",
      "start_date": "2021-12-16",
      "completion_date": "2025-05-28",
      "enrollment": 0,
      "sponsor": "Vor Biopharma"
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE3": 3,
      "": 1,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "TERMINATED": 4,
      "WITHDRAWN": 1,
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Generalized Myasthenia Gravis",
      "Leukemia, Myeloid, Acute",
      "Leukemia, Myeloid, Acute, Myelodysplastic Syndromes",
      "Systemic Lupus Erythematosus"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:22:50.131454",
    "search_query": "Vor Biopharma Inc.",
    "url": "https://clinicaltrials.gov/search?term=Vor+Biopharma+Inc."
  }
}